Biodesix raises $11.7M via private placement; amends 2021 term loan with SVB

BIODESIX INC

Sold 6,508,376 shares at $1.79/share to consortium including board members, raising ~$11.7M.
Third Amendment to 2021 Term Loan: repays $3M in April 2022 and $2M later; waives Q1 2022 minimum revenue requirement.
Waiver of prepayment fee on $3M repayment; consent for $2M milestone payment under Integrated Diagnostics purchase agreement.
Reaffirms 2022 revenue guidance of $37.5M-$39.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.